-- (Updates with latest stock price movement in the headline and first paragraph, and previous adjusted EPS guidance in the seventh paragraph.)
Abbott Laboratories (ABT) shares were down about 4% in Thursday trading after the company reported Q1 results and lowered 2026 guidance.
The company reported Q1 adjusted earnings earlier Thursday of $1.15 per diluted share, up from $1.09 a year earlier.
Analysts polled by FactSet expected $1.14.
Net sales for the quarter ended March 31 was $11.16 billion, up from $10.36 billion a year earlier.
Analysts polled by FactSet expected $11.00 billion.
For Q2, Abbott projects adjusted diluted earnings of $1.25 to $1.31 per share. Analysts expect $1.36.
The company said it now expects full-year 2026 adjusted earnings of $5.38 to $5.58 per diluted share, compared with its prior guidance of $5.55 to $5.80. Analysts expect $5.60.
The company expects full-year 2026 comparable sales growth of 6.5% to 7.5%.
Price: $97.13, Change: $-4.44, Percent Change: -4.37%